UK shares and the pound started the week sharply lower after Brexit talks stumbled yet again and a new strain of the virus led to even more draconian rules on personal movement.

New emergency Tier Four restrictions created chaos for people travelling ahead of Christmas while many European countries have suspended inbound travel from the UK.

At 9am the FTSE 100 was 72 points or 1.1% lower at 6,457 points. Airlines and the hospitality sector took the brunt of the selling while mining companies benefited from the weakness in sterling.

The pound slumped 2% against the US dollar to $1.32 while Brent Crude prices were 3.3% lower at $50.6 per barrel. Gold jumped 1% to $1,898 an ounce.

Seemingly bucking the trend was China where the SE Composite index of shares gained 0.9%.

NEWS ROUND UP

Oil major Royal Dutch Shell (RDSB) said it expects to book net charges of between $3.5 billion and $4.5 billion in the fourth quarter, in relation to impairments, asset restructuring and onerous contracts.

Shell said the charges were linked to its upstream business, including a partial impairment of the Appomattox asset in the US Gulf of Mexico, plus its oil products and integrated gas businesses.

Adjusted earnings at its upstream business were expected to show a loss in the current price environment. The company will present a strategic update to investors on 11 February 2021. Shares dropped almost 5% to £12.78.

Sports Direct owner Frasers (FRAS) pulled guidance for its annual performance after it was forced to shutter stores in large parts of England in the wake of the latest government coronavirus restrictions.

Given this is the peak trading period for retailers, and with the likelihood of further rolling lockdowns nationwide over the coming months, Frasers said it could no longer commit to meeting its guidance of achieving a 20% to 30% improvement in underlying earnings before interest, taxes, depreciation and amortization (EBITDA). Shares sank 6% to 448.5p.

NatWest (NWG) said it had agreed to acquire a £3.0 billion portfolio of prime UK mortgages from challenger lender Metro Bank (MTRO) for £3.1 billion. NatWest said the purchase represented a 2.7% premium to gross book value.

The portfolio consists of owner-occupied residential mortgages with a weighted average current loan to value of around 60%. NatWest shares dropped 5% to 149.5p while Metro Bank shares rallied 12% to 128p.

Property investor Stenprop (STP) said it had agreed to sell its freehold interest in the Victoria Centre in Berlin to Art-Invest Real Estate Funds for €37.5 million.

Stenprop said the disposal price was at its 30 September book value and reflected a 19.3% premium to the 31 March book value.

It added that the deal was in line with its strategy of becoming entirely invested in multi-let industrial properties via the sale of non-core assets.

Net proceeds from the sale after deduction of anticipated transaction costs, repayment of debt and property taxes were expected to be €24.1 million. Shares gave up 0.4% to 133.5p.

Aviation services group Signature Aviation (SIG) said its board had indicated to Blackstone that it would ‘currently be minded to recommend a firm offer’ for the company.

Blackstone Infrastructure Advisors and Blackstone Core Equity Management Associates had offered $5.17 per Signature share, equating to £3.86 in sterling and a 44% premium to the company's closing price on 16 December. Shares gained 0.9% to 372.1p.

HEATHCARE NEWS

Pharmaceutical company GlaxoSmithKline (GSK) said ViiV Healthcare, its joint venture company with Pfizer and Shionogi, had won marketing approval for its combination injection to treat HIV-1 in adults who were virologically suppressed.

The long-acting injectable regimen was preferred by majority of clinical trial patients who tried the treatment over their previous daily oral therapy, ViiV Healthcare said. Shares added 1% to £13.7.

Pharmaceutical giant AstraZeneca (AZN) said its non-small cell lung cancer drug Tagrisso had been approved under the US Food and Drug Administration's (FDA) real-time oncology review pilot program.

In a separate statement, AstraZeneca said the FDA had requested further clarifying analyses of clinical data, to complete its review of the new drug application for roxadustat to treat patients with anemia of chronic kidney disease. The shares gained 0.1% to £75.1.

FOR A LIST OF FTSE 100 GAINERS AND LOSERS SEE HERE

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Issue Date: 21 Dec 2020